Central Canada includes Manitoba, Nunavut and Saskatchewan!

Here in the Central Region for Crohn's and Colitis Canada, we have a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and health professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved. Every community, large or small, has the potential to help us improve the lives of those affected by Crohn’s disease and ulcerative colitis, and bring us closer to finding cures.

Outside Manitoba: 1-866-856-8551 (toll free)
Manitoba Mailing Address
PO Box 58039 Bishop Grandin PO
Winnipeg MB R2M 2R6
R2M 2R6

Outside Saskatoon: 1-844-664-4420
Saskatchewan Mailing Address
P.O. Box 28074 RPO Westgate
Saskatoon, SK
S7N 5V8

Family sitting on the floor of their living room playing

Caregiver Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?  Join our upcoming Peer Connect ...

 • 
Virtual
 • 
Speaker giving a presentation

Pain in Crohn's and Colitis

DetailsDate: December 5, 2024 Time: 7:00 - 8:30 p.m. ETAre you or a loved one struggling with pain when living with Crohn's disease or ulcerative colitis? Have you ever wondered why some pain ...

 • 
ZOOM (Virtuel)
 • 
Group of friends who are older adults chatting with each other

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?  Join our upcoming Peer Connect event ...

 • 
Virtual
 • 
Remember to bookmark this page.

Winnipeg Office

PO Box 58039 Bishop Grandin PO
Winnipeg Manitoba R2M 2R6

manitoba@crohnsandcolitis.ca 204-688-9076 1-866-856-8551

Search by Postal Code

News

“You don’t need to be superhuman”: How a small-town hockey player made it to the NCAA in the face of Crohn’s disease

“You don’t need to be superhuman”: How a small-town hockey player made it to the NCAA in the face of Crohn’s disease

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head

 39 40 41 42 43 44 45 46 47 48